Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2025)

Indivior Pharmaceuticals has reported Other Non-Current Liabilities over the past 5 years, most recently at $21.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $21.0 million for Q4 2025, up 16.67% from a year ago — trailing twelve months through Dec 2025 was $21.0 million (up 16.67% YoY), and the annual figure for FY2025 was $21.0 million, up 16.67%.
  • Other Non-Current Liabilities for Q4 2025 was $21.0 million at Indivior Pharmaceuticals, down from $30.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for INDV hit a ceiling of $474.0 million in Q4 2021 and a floor of $5.0 million in Q4 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $19.5 million (2024), compared with a mean of $76.8 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 98.95% in 2022 and later soared 520.0% in 2023.
  • Indivior Pharmaceuticals' Other Non-Current Liabilities stood at $474.0 million in 2021, then plummeted by 98.95% to $5.0 million in 2022, then soared by 520.0% to $31.0 million in 2023, then tumbled by 41.94% to $18.0 million in 2024, then increased by 16.67% to $21.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $21.0 million (Q4 2025), $30.0 million (Q3 2025), and $18.0 million (Q2 2025) per Business Quant data.